Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | El-Damasy, Ashraf Kareem | - |
dc.contributor.author | Cho, Nam-Chul | - |
dc.contributor.author | Pae, Ae Nim | - |
dc.contributor.author | Kim, Eunice Eunkyeong | - |
dc.contributor.author | Keum, Gyochang | - |
dc.date.accessioned | 2024-01-20T04:00:28Z | - |
dc.date.available | 2024-01-20T04:00:28Z | - |
dc.date.created | 2021-09-04 | - |
dc.date.issued | 2016-07-15 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/123871 | - |
dc.description.abstract | A series of new 2-anilinoquinolines possessing 3-(morpholino or 4-methylpiperazin-1-yl) propoxy moiety at C5 of quinoline has been designed and synthesized as potential anticancer agents. Their antiproliferative activities were evaluated against a panel of 60 cancer cell lines at NCI and compared with gefitinib as a reference compound. Most of the tested compounds displayed potent and broad spectrum antiproliferative activities. Compounds 7d, 7f and 7g showed strong inhibitory and lethal effects at 10 mu M concentration. Moreover, they manifested superior potencies and efficacies than gefitinib across the most tested cell lines. Compound 7d, with 4-chloro-3-trifluoromethylphenyl group, proved to be the most potent and efficacious derivative in this series, with mean GI(50) and TGI values of 1.62 mu M and 3.47 mu M, respectively. Kinase screening of 7d against a panel of 47 oncogenic kinases revealed its selective inhibitory effect (96% inhibition) towards TrkA kinase. Furthermore, the most potent compounds showed low cytotoxic effects against HFF-1 normal cell line. (C) 2016 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.publisher | Pergamon Press Ltd. | - |
dc.subject | NERVE GROWTH-FACTOR | - |
dc.subject | ANTICANCER AGENTS | - |
dc.subject | TYROSINE KINASES | - |
dc.subject | BREAST-CANCER | - |
dc.subject | IN-VITRO | - |
dc.subject | PAN-TRK | - |
dc.subject | INHIBITOR | - |
dc.subject | DISCOVERY | - |
dc.subject | EXPRESSION | - |
dc.subject | POTENT | - |
dc.title | Novel 5-substituted-2-anilinoquinolines with 3-(morpholino or 4-methylpiperazin-1-yl)propoxy moiety as broad spectrum antiproliferative agents: Synthesis, cell based assays and kinase screening | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.bmcl.2016.05.047 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | Bioorganic & Medicinal Chemistry Letters, v.26, no.14, pp.3307 - 3312 | - |
dc.citation.title | Bioorganic & Medicinal Chemistry Letters | - |
dc.citation.volume | 26 | - |
dc.citation.number | 14 | - |
dc.citation.startPage | 3307 | - |
dc.citation.endPage | 3312 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000377471400021 | - |
dc.identifier.scopusid | 2-s2.0-84969964186 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | NERVE GROWTH-FACTOR | - |
dc.subject.keywordPlus | ANTICANCER AGENTS | - |
dc.subject.keywordPlus | TYROSINE KINASES | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | PAN-TRK | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | DISCOVERY | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | POTENT | - |
dc.subject.keywordAuthor | 2-Anilinoquinolines | - |
dc.subject.keywordAuthor | Antiproliferative activity | - |
dc.subject.keywordAuthor | 3-(Morpholino)propoxy | - |
dc.subject.keywordAuthor | 3-(4-Methylpiperazin-1-yl)propoxy | - |
dc.subject.keywordAuthor | TrkA kinase | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.